Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?

Key Points

• Prediction of cardiovascular event outcomes may benefit from data gathered in phase 2/3 clinical trials, enhancing the understanding of treatment effects.
• Among the limitations considered are the drugs studied and variability in major adverse cardiovascular events (MACE) definitions.

Structured PICO

Abstract